Onyx Pharmaceuticals Announces a Teleconference and Webcast To Provide An Update On Nexavar And Report Full Year 2007 Financial Results

EMERYVILLE, Calif. — Feb. 19, 2008

Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to provide an update on Nexavar® (sorafenib) tablets, as well as to discuss fourth quarter and full year 2007 financial results, on Tuesday, February 19, 2008, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time). Financial results for the fourth quarter and year ended December 31, 2021 will be released today.

Interested parties may access a live webcast of the presentation on our website at:
http://www.onyx-pharm.com/view.cfm/32/Event-Calendar
or by dialing 847-413-3238 and using the passcode 20751832. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 20751832 approximately one hour after the teleconference concludes. The replay will be available through March 19, 2008.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treatedTM. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of advanced kidney cancer and for the treatment of liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other tumor types. For more information about Onyx, visit the company’s website at: www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.

Return to 2008 Press Releases